gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate has been researched along with Malignant Melanoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akbari-Zadeh, H; Aminolroayaei, F; Birgani, FF; Maghsoudinia, F; Samani, RK; Shanei, A | 1 |
| Brasch, RC; Chaopathomkul, B; Cyran, CC; Fu, Y; Rogut, V; Shames, DM; Wendland, MF | 1 |
| Botta, M; Catanzaro, V; Filippi, M; Patrucco, D; Tei, L; Terreno, E | 1 |
| Aime, S; Arena, F; Gianolio, E; Singh, JB; Stefanìa, R | 1 |
| Allegrini, PR; Baumann, D; Becquet, M; Brecht, K; Brueggen, J; Ferretti, S; McSheehy, PM; Rausch, M; Rudin, M; Schaeffer, F; Schnell, C; Wood, J | 1 |
5 other study(ies) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Malignant Melanoma
| Article | Year |
|---|---|
Ultrasound responsive Gd-DOTA/doxorubicin-loaded nanodroplet as a theranostic agent for magnetic resonance image-guided controlled release drug delivery of melanoma cancer.
Topics: Animals; Cell Line, Tumor; Delayed-Action Preparations; Doxorubicin; Drug Delivery Systems; Heterocyclic Compounds; Magnetic Resonance Imaging; Melanoma; Mice; Organometallic Compounds; Precision Medicine; Theranostic Nanomedicine; Ultrasonography | 2022 |
Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capsules; Cell Line, Tumor; Contrast Media; Drug Monitoring; Heterocyclic Compounds; Humans; Macromolecular Substances; Magnetic Resonance Imaging; Melanoma; Neovascularization, Pathologic; Organometallic Compounds; Polyethylene Glycols; Rats; Rats, Nude; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2013 |
First in vivo MRI study on theranostic dendrimersomes.
Topics: Animals; Cell Line, Tumor; Contrast Media; Dendrimers; Female; Glucocorticoids; Heterocyclic Compounds; Human Umbilical Vein Endothelial Cells; Humans; Magnetic Resonance Imaging; Melanoma; Mice; Mice, Inbred C57BL; Nanocapsules; Organometallic Compounds; Prednisolone; Theranostic Nanomedicine | 2017 |
β-Gal gene expression MRI reporter in melanoma tumor cells. Design, synthesis, and in vitro and in vivo testing of a Gd(III) containing probe forming a high relaxivity, melanin-like structure upon β-Gal enzymatic activation.
Topics: Animals; beta-Galactosidase; Cell Line, Tumor; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Magnetic Resonance Imaging; Melanoma; Mice; Mice, Inbred C57BL; Monophenol Monooxygenase; Organometallic Compounds | 2011 |
PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Contrast Media; Female; Heterocyclic Compounds; Magnetic Resonance Imaging; Melanoma; Metabolic Clearance Rate; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Organometallic Compounds; Phthalazines; Protein-Tyrosine Kinases; Pyridines; Vascular Endothelial Growth Factor A | 2005 |